Samarth Kulkarni
Samarth Kulkarni is a biotechnology executive. Kulkarni is the Chief Executive Officer and Chairman of the Board at CRISPR Therapeutics. He has served as CEO of CRISPR Therapeutics since 2017. He was appointed to CEO and Chairman of CRISPR Therapeutics in 2023.[1]
Early life and education[edit]
Kulkarni was born in Belagavi, India and he moved to the U.S. to pursue his Ph.D. at the University of Washington.
Kulkarni earned a B. Tech. from the Indian Institute of Technology and received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics.[2]
Career[edit]
Kulkarni served as a partner at McKinsey & Company. As part of his nine-year tenure at McKinsey, he co-led the company’s biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy.[3]
Kulkarni joined CRISPR in 2015 as Chief Business Officer. He was appointed to President and Chief Business Officer before becoming CEO in 2017. Kulkarni was appointed to CEO and Chairman in 2023.[4]
Kulkarni leads CRISPR Therapeutics, a biotechnology company founded on the Nobel Prize-winning CRISPR/Cas9 technology, as the company advances product candidates for disease areas including blood diseases, cancer, type 1 diabetes, cardiovascular diseases and rare diseases.[5][6][7]
CRISPR Therapeutics co-developed CASGEVY™ (exagamglogene autotemcel), the first approved CRISPR/Cas9 gene-edited therapy, in collaboration with Vertex Pharmaceuticals Incorporated. CASGEVY has been approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.[8]
Boards and recognition[edit]
Kulkarni currently serves on the Board of Directors of Centessa Pharmaceuticals and two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics.[9][10][11]
Previously, Kulkarni served as Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. He has also served on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO).[12][13]
In 2023, the American India Foundation, known as AIF, a non-profit organization, honored Kulkarni at its 17th Annual New England Gala. The AIF is focused on catalyzing social and economic change in India and building a lasting bridge between the United States and India through interventions in education, livelihoods, public health, and leadership development, with a particular emphasis on empowering girls and women to achieve gender equity.[14]
In 2020, Kulkarni was awarded the “best biopharma CEO” from STAT News, a news platform focused on the biopharma industry. The “best biopharma CEO” was voted upon by STAT readers. The article cites that Kulkarni leads “a company that is leveraging the CRISPR/Cas-9 gene-editing platform to craft curative treatments for patients with inherited diseases and cancer.” [15]
Kulkarni frequently speaks on news stations including CNBC and at prominent events including The Wall Street Journal Health Forum, The International Vatican Conference, The Hill’s Health Reimagined: The Future of Healthcare, The Forbes Healthcare Summit, Future Investment Initiative (FII) in Saudi Arabia, Financial Times U.S. Pharma and Biotech Summit, and CNBC Healthy Returns.[16][17][18][19][20][21][22][23][24]
References[edit]
- ↑ "CRISPR Therapeutics Announces Leadership Transition". Yahoo Finance. September 7, 2023.
- ↑ "Samarth Kulkarni from Belagavi is Now CEO of CRISPR Therapeutics". Belagavi Latest News. October 25, 2017.
- ↑ "CRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer". Fierce Biotech. August 14, 2015.
- ↑ "CRISPR Therapeutics".
- ↑ "FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease". Scientific American. December 8, 2023.
- ↑ "FDA Approves First CRISPR Treatment in U.S." Time. December 11, 2023.
- ↑ "FDA Approves New CRISPR Gene-Editing Treatment". Forbes. January 16, 2024.
- ↑ "Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia". Fierce Pharma. January 16, 2024.
- ↑ "Centessa Pharmaceuticals".
- ↑ "Black Diamond Therapeutics".
- ↑ "Repare Therapeutics".
- ↑ "Market Screener". Market Screener. February 23, 2024.
- ↑ "Biotechnology Innovation Organization Emerging Companies". Biotechnology Innovation Organization.
- ↑ "AIF to Honor Life Sciences Icons Reshma Kewalramani and Samarth Kulkarni". India New England News. March 31, 2023.
- ↑ "Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list". Stat News. December 18, 2020.
- ↑ "CRISPR Therapeutics CEO talks winning FDA approval for sickle cell anemia treatment". CNBC. December 11, 2023.
- ↑ "CRISPR Therapeutics CEO: Science in gene editing is moving at breakneck speed". CNBC. February 29, 2024.
- ↑ "Gene Editing's Big Moment". Wall Street Journal. February 21, 2024.
- ↑ "The Cura Foundation: The Future of CRISPR Based Therapies for Disease". The Cura Foundation YouTube. May 11, 2021.
- ↑ "The Hill Events: Health Reimagined, The Future of Healthcare". The Hill Events YouTube. July 10, 2020.
- ↑ "2021 Forbes Healthcare Summit: Breakthrough Solutions for the Next Decade". December 2, 2021.
- ↑ "FII Institute: What's Next for Biomedical Research". FII Institute YouTube. January 23, 2020.
- ↑ "Financial Times: US Pharma and Biotech Summit – Panel – Delivering on the potential of personalized medicine". July 26, 2019.
- ↑ "Highlights from CNBC's Healthy Returns conference". CNBC. May 24, 2019.
This article "Samarth Kulkarni" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Samarth Kulkarni. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
